Entrada Therapeutics (TRDA) Net Margin (2023 - 2026)
Entrada Therapeutics (TRDA) recorded quarterly Net Margin of 4539.09% in Q1 2026, down 50.43% quarter-over-quarter from 3017.4% in Q4 2025, and down 445470.0% on a YoY basis from N/an in Q1 2025.
Entrada Therapeutics (TRDA) Net Margin (2023 - 2026) Analysis & Trends
Entrada Therapeutics' Net Margin history runs 4 years deep, the most recent figure standing at 4539.09% for Q1 2026.
- In Q1 2026, Net Margin fell 445470.0% year-over-year to 4539.09%; the TTM figure through Mar 2026 stood at 2896.79% (down 291114.0% YoY), while the FY2025 annual figure was 565.48%, down 59659.0% from the prior year.
- Net Margin was 4539.09% for Q1 2026 at Entrada Therapeutics, down from 3017.4% in the prior quarter.
- In the past five years, Net Margin ranged from a high of 81.09% in Q3 2023 to a low of 4539.09% in Q1 2026.
- Historically, Net Margin has averaged 974.71% across 4 years, with a median of 71.5% in 2024.
- The sharpest annual moves came in 2024 and 2026: Net Margin soared 20077 bps in 2024, then sank 445470 bps in 2026.
- A 4-year view of Net Margin shows it stood at 22.6% in 2023, then jumped by 113 bps to 2.84% in 2024, then slumped by 106457 bps to 3017.4% in 2025, then tumbled by 50 bps to 4539.09% in 2026.
- The last three Net Margin figures came in at 4539.09% (Q1 2026), 3017.4% (Q4 2025), and 2737.3% (Q3 2025), per Business Quant data.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Net Margin (Qtr) |
|---|---|---|---|---|---|
| 1 | Alterity Therapeutics | 925,601.88 Bn | 925,601.85 Bn | - | - |
| 2 | Belite Bio | 58,560.00 Bn | 58,560.00 Bn | - | - |
| 3 | Quantum Biopharma | 17,284.41 Bn | 17,284.40 Bn | - | - |
| 4 | Legend Biotech | 2,809.00 Bn | 2,808.71 Bn | 242.10 Mn | 0.82% |
| 5 | Evaxion A | 1,334.43 Bn | 1,334.42 Bn | - | - |
| 6 | Akari Therapeutics | 1,312.27 Bn | 1,312.26 Bn | - | - |
| 7 | Psyence Biomedical | 212.16 Bn | 212.16 Bn | - | - |
| 8 | Vertex Pharmaceuticals | 114.83 Bn | 107.58 Bn | 2.59 Bn | 34.53% |
| 9 | Abivax | 91.96 Bn | 91.96 Bn | - | - |
| 10 | Entrada Therapeutics | 295.36 Mn | 295.36 Mn | - | -4,539.09% |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -4,539.09% |
| Dec 31, 2025 | -3,017.40% |
| Sep 30, 2025 | -2,737.30% |
| Jun 30, 2025 | -2,211.54% |
| Mar 31, 2025 | -84.39% |
| Dec 31, 2024 | 2.84% |
| Sep 30, 2024 | -71.50% |
| Jun 30, 2024 | 58.07% |
| Mar 31, 2024 | 39.74% |
| Dec 31, 2023 | -22.60% |
| Sep 30, 2023 | 81.09% |
| Jun 30, 2023 | -142.70% |
| Mar 31, 2023 | -26.42% |